ABIOMED

ABIOMED FCF per Share

Delisted

The Free Cash Flow per Share of ABIOMED (ABMD) as of Nov 7, 2026 is 5.43 USD. In the previous year, Free Cash Flow per Share was 4.81 USD — a change of 12.85% (higher).

FCF per Share

5.43USD

YoY

12.85%

Last updated:

Free Cash Flow per Share of ABIOMED is 2022 5.43 USD. Free Cash Flow per Share of ABIOMED was 2021 4.81 USD. It decreases by 12.85% higher compared to the previous year.

The ABIOMED FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2015
0.89 USD
Jan 1, 2016
1.36 USD
Jan 1, 2017
1.44 USD
Jan 1, 2018
2.97 USD
Jan 1, 2019
4.53 USD
Jan 1, 2020
5.89 USD
Jan 1, 2021
4.81 USD
Jan 1, 2022
5.43 USD
The ABIOMED FCF per Share history
YEARFCF per ShareYoY
5.43USD+12.85%
4.81USD-18.35%
5.89USD+30.13%
4.53USD+52.32%
2.97USD+106.66%
1.44USD+5.77%
1.36USD+53.41%
0.89USD+79.74%
0.49USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

ABIOMED Stock analysis

What does ABIOMED do? Abiomed Inc. is one of the most innovative companies in the medical technology industry. It was founded in 1981 and is headquartered in Danvers, Massachusetts. The company specializes in the development, manufacturing, and marketing of medical devices aimed at saving or improving patients' lives. Abiomed started as a small company focused on implantation technology for cardiac arrhythmias. However, the company soon recognized the need to concentrate on providing solutions for cardiac intensive care. Today, Abiomed is a leader in the field of cardiopulmonary support systems and offers innovative devices to support the heart. Abiomed's business model revolves around leveraging its expertise in medical technology for cardiology interventions and intensive care and bringing innovative products to market. The company has industry experts and doctors on its team who contribute to the development and manufacturing of products. This highest level of professionalism is also reflected in the distribution channels Abiomed utilizes, with a focus on delivering its products to clinics specialized in critical medical interventions. Abiomed is divided into various business segments that concentrate on the medical devices the company offers. One of these segments is the Impella portfolio, which focuses on heart pumps for acute heart failure. These pumps are capable of supporting the heart during cardiological intervention by pumping blood into the heart while artificially ventilating it. The Impella portfolio is recognized as a standard in cardiac intensive care. Another important area for Abiomed is product development. The company heavily invests in researching and developing new products to meet the current demand in cardiology on the market. Abiomed is aware that rapid development of new products can provide a competitive advantage and, therefore, is an essential part of its business model. The technology offered by Abiomed is revolutionary and allows for the treatment of patients with acute heart failure, which was previously difficult or impossible. This is a significant milestone for the company and the healthcare industry in general. Abiomed is aware of its responsibility towards patients, doctors, and hospitals and is continuously working to develop innovative solutions for the healthcare industry. In summary, Abiomed Inc. is a leading company in the medical technology industry that focuses on cardiology intervention and intensive care. The company is innovative and offers products that can save and improve patients' lives. The Impella portfolio, specializing in acute heart failure, is an important part of its business model. Abiomed heavily invests in research and development to consistently provide innovative solutions to its customers. ABIOMED is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ABIOMED stock

Free Cash Flow per Share of ABIOMED is 5.43 USD in 2022.

Free Cash Flow per Share of ABIOMED changed from 4.81 USD to 5.43 USD, representing a 12.85% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share ABIOMED since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — ABIOMED

All Key Metrics — ABIOMED